The Gray Market: Sourcing, Purity, and Contamination

Most “research peptides” sold online move through a supply chain built to look like laboratory reagents while functioning as a consumer market. People turn to it for understandable reasons — a compound with promising early research often has no approved product, no prescriber willing to write for it, or a brand-name price that puts the approved version out of reach. This page isn’t here to talk you out of anything or to police your choices; it’s here to explain how the market actually works so you can judge what you’re handling. Reference and harm-reduction information, not medical advice, and nothing here is a protocol.

How the supply actually works

A large share of research peptides are synthesized at bulk facilities (many overseas), sold to resellers, and split into small vials under brand names. At the consumer end they are labeled “Research Use Only” (RUO) or “not for human consumption.” That phrase is a legal framing, not a quality grade: it lets a seller avoid the testing, sterility, and labeling rules that apply to drugs, while implicitly leaving administration to the buyer. The FDA treats this disclaimer skeptically. In September 2025 it issued more than 50 warning letters to companies marketing compounded GLP-1 drugs and other peptides, with most issued on September 9, 2025. A related strand of enforcement has targeted RUO-labeled products whose own advertising made clear the items were intended for people — for example, marketing weight-loss benefits or otherwise indicating human use. In its December 2024 letter to Summit Research Peptides, the FDA concluded that website and social-media claims established the products were “intended to be drugs for human use” despite the research-use disclaimer.

RUO labeling means no one is required to verify what is in the vial, that it is the right molecule, that it is sterile, or that one batch matches the next.

Why purity and even identity vary

Solid-phase peptide synthesis is error-prone. Each coupling step can fail, producing truncated chains, deletion sequences, incomplete deprotection, and other byproducts that ride along into the final product. Purity is normally measured by HPLC (how much of the sample is the main peak) and identity by mass spectrometry (whether that peak is actually the intended molecule). A certificate of analysis that shows only HPLC tells you something is present at a given level — not that it is the compound you ordered.

The variation is not theoretical. An analysis of more than 5,000 peptide samples by the testing firm Finnrick, reported by MIT Technology Review in February 2026, found that vials sold as BPC-157 sometimes contained none of the compound, and that among those that did, measured purity ranged from roughly 82% to 100%. Quality differed not just between vendors but between batches from the same vendor.

Contamination is a separate problem

Purity and sterility are different questions, and both matter for anything injected. The same Finnrick analysis reported that 8% of tested peptide samples carried measurable endotoxins — fragments of bacterial cell walls that are heat-stable and small enough to pass through a sterilizing (0.22-micron) filter, surviving processes that kill living bacteria, including autoclaving. Endotoxins can cause fever, chills, and in larger amounts dangerous drops in blood pressure. A vial can be free of living bacteria and still be pyrogenic, because sterilization and depyrogenation are not the same thing. Beyond endotoxin, the FDA has flagged that compounded “semaglutide” can contain unknown impurities (a manufacturer analysis cited by Pharmacy Times reported levels reaching 33%) and unapproved salt forms such as semaglutide sodium and semaglutide acetate, which the FDA describes as different active ingredients from the approved drug and which have not been shown to be safe or effective.

Mislabeling and the limits of “technique”

Because identity itself is unreliable, a vial may contain the wrong peptide, a mixture, a different salt form, or filler. No amount of careful reconstitution math, aseptic handling, or storage discipline can correct a bad starting material. Reconstitution is genuinely just arithmetic — concentration equals mass of peptide divided by volume of diluent — but that math is only meaningful if the labeled mass and identity are true. Good technique on top of an unknown input produces a precisely measured unknown.

Legal and sport status

These products are not approved for human use. BPC-157 was added to the WADA Prohibited List in 2022 under category S0 (Non-Approved Substances) — in fact it was the first substance named as an example in that section — and is banned at all times in WADA-governed sport. USADA notes there is no basis for a therapeutic use exemption because it is not an approved therapeutic agent in any country, and warns athletes specifically never to use a product marketed for “research only.” Many growth-hormone secretagogues and releasing peptides — for example ipamorelin, the GHRPs, CJC-1295, and ibutamoren (MK-677) — fall under the separate S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics).

Bottom line

None of this is a verdict on the compounds themselves. “Unapproved” usually means a molecule hasn’t been through the trials approval requires — often because no company has a commercial reason to fund them — not that it has been shown to be dangerous. The narrower, practical point is this: in the gray market the label tells you what a seller is allowed to claim, not what is in the vial. Purity, identity, and sterility all vary, sometimes drastically, and no handling skill compensates for a contaminated or misidentified input. Sending a sample to an independent lab is the one move that replaces a seller’s claim with an actual measurement.

Sources

• FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• Health Law Alliance — FDA Targets GLP-1 and Peptide Compounding, Advertising and “Research Use Only” Labeling
• FDA — Warning Letter, Summit Research Peptides (695607), 12/10/2024
• MIT Technology Review — Peptides are everywhere. Here’s what you need to know. (Feb 2026)
• USADA — BPC-157: Experimental Peptide Creates Risk for Athletes
• WADA — The Prohibited List
• Pharmacy Times — Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients
• Peptide purity testing: HPLC quantifies the main peak; mass spectrometry confirms identity; common synthesis byproducts include truncated and deletion sequences (general analytical-chemistry reference; no single canonical URL)